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Spinal muscular atrophy (SMA) is a neuromuscular disease caused by mutations in Survival 
Motor Neuron 1 (SMN1), leading to degeneration of alpha motor neurons (MNs) but also 
affecting other cells. Induced pluripotent stem cell (iPSC)-derived human MN models from 
severe SMA patients have shown relevant phenotypes. We have produced and fully characterized 
iPSCs from members of a discordant consanguineous family with chronic SMA. We 
differentiated the iPSC clones into ISL-1+/ChAT+ MNs and performed a comparative study 
during the differentiation process, observing significant differences in neurite length and number 
between family members. Analyses of samples from wild-type, severe SMA type I and the type 
IIIa/IV family showed a progressive decay in SMN protein levels during iPSC-MN 
differentiation, recapitulating previous observations in developmental studies. PLS3 underwent 
parallel reductions at both the transcriptional and translational levels. The underlying, progressive 
developmental decay in SMN and PLS3 levels may lead to the increased vulnerability of MNs in 
SMA disease. Measurements of SMN and PLS3 transcript and protein levels in iPSC-derived 
MNs show limited value as SMA biomarkers. 
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INTRODUCTION 
 
SMA is an autosomal recessive neuromuscular disease caused by mutations in the Survival of 
Motor Neuron 1 gene (SMN1), which result in decreases in SMN protein levels 
1,2
. Degeneration 
of alpha motor neurons (MNs) in the ventral horn of the spinal cord, atrophy of skeletal muscles 
and generalized weakness are hallmarks of the disorder 
3,4
. SMA is clinically divided in four 
types broadly grouped by age of onset and highest motor function achieved. In the most severe 
form (SMA type I), the onset of the disease occurs before 6 months of age and patients usually 
die within the first two years of life. Type II SMA is the intermediate form; affected patients 
never walk. Type III disease is characterized by patients who are able to walk; depending on the 
onset of symptoms, patients can be classified as type IIIa (onset before 3 years) or type IIIb (after 
3 years). In SMA type IV, the onset of the pathology occurs within the second or third decade of 
life and patients only display mild motor impairment 
5,6
. 
 
Two SMN genes are present in the human genome: SMN1 (telomeric) and SMN2 (centromeric) 
1
. 
SMN1 mostly produces full-length mRNA (FL-SMN) and functional protein, while SMN2 mainly 
produces an alternatively spliced isoform with no exon seven (Δ7-SMN), which is thought to 
encode a less functional and rapidly degraded truncated protein 
7,8
. Depending on the tissue, 
about 10-50% of the SMN2 pre-mRNA can be properly spliced and produce functional SMN 
9,10
. 
SMN is ubiquitously produced and the specific susceptibility of MNs is not understood 
2
. 
Observations in SMA patients and mouse models demonstrate the involvement of non-neural 
tissues in the disease 
11
. It has been proposed that all cells are in a vulnerability-resistance 
spectrum in regards to SMN reduction, MNs being located at the most sensitive end 
12
. 
 
The number of SMN2 copies is the most important known phenotypic modifier of the disease, 
since a higher number of SMN2 copies correlates with higher production of properly spliced SMN 
mRNA and thus functional SMN 
13,14
, but this correlation is not always absolute 
15
. Siblings with 
the same SMN1-SMN2 genotype but discordant phenotype have been described in SMA families 
16-21
. High levels of plastin 3 (PLS3) in lymphoblasts and blood have been associated with a 
positive modifier effect on SMA severity in discordant female siblings 
22-24
, but there seem to be 
additional unknown modifier factors regulating the severity of the disease 
25
. We have worked 
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extensively with an SMA family in which four discordant sisters born from consanguineous 
parents are homozygous for a 4-bp deletion in SMN1 exon 3 (c.399_402delAGAG). This 
mutation produces a frame-shift that predicts a stop codon 40-bp downstream 
21,26
. Despite 
presenting the same SMN1 mutation and identical SMN2 copy number (n=4), the clinical 
manifestations in the four sisters range from early onset SMA type IIIa to SMA type IV with 
minimal manifestations. 
 
The recent derivation and further differentiation of iPSCs from patients with type I SMA has 
provided new models to study the disease and shown MN phenotypes in cell culture 
27-30
. Here 
we report the production and differentiation of iPSC lines derived from members of the 
c.399_402delAGAG family, who present with less severe phenotypes. Differentiation of these 
novel iPSCs towards the MN lineage showed mild neurite defects in the affected sisters 
compared to the carrier mother but no obvious effect in neuroepithelial-derived spheres (Nsphs)-
myotube co-cultures. We show a progressive decline of SMN and PLS3 levels during the iPSC to 
MN differentiation, confirmed in wild-type and unrelated type I SMA iPSCs. Finally, we discuss 
the limitations of SMN and PLS3 transcript and protein levels as SMA biomarkers, even when the 
measurements are obtained from iPSC-derived MN cultures. 
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RESULTS 
 
Generation and characterisation of iPSCs 
 
We generated several iPSC clones from skin fibroblast from four family members (M, S1, S3, 
S4) through retroviral transduction with Yamanaka’s set of reprogramming factors 31 (Fig. 1A). 
One clone from each individual was selected and further propagated and characterised rendering 
four stable iPSC lines: M-26, S1-28, S3-63 and S4-32. All selected clones showed successful 
reprogramming as judged by the expression of pluripotency markers (Supplementary Fig. S1 and 
S2), down-regulation of exogenous transgenes and up-regulation of their endogenous expression 
(Supplementary Fig. S3) and in vitro and in vivo differentiation potential (Fig. 1B, C). 
Furthermore, DNA fingerprinting confirmed the identity of the clones and karyotype analysis 
showed no obvious chromosomal aberration (Supplementary Table S1 and Fig. S4).  
 
 
iPSC-MN differentiation and patient-specific differences in neurite outgrowth 
 
We differentiated the four iPSC lines from the family under study into MNs following an 
embryoid body (EB)-based differentiation protocol for human embryonic stem cells (hESCs) 
32
 
(Fig. 2). iPSCs were cultured in suspension as EBs for seven days to induce loss of pluripotency 
and initial differentiation into a neuronal fate. Twelve to fourteen days (12-14D) after the start of 
the differentiation protocol PAX6+/SOX1+ neural tube-like rosettes were observed 
(Supplementary Fig. S5). Rosettes were selected manually and cultured in suspension as 
differentiating Nsphs for variable lengths of time depending on the experiment. By D28, most of 
the cells in the Nsphs were olig2+ MN progenitors. Plating of D28 Nsphs and culture in MN-
specific conditions for 1-2 weeks (D35-47) induced cell cycle arrest, the appearance of ISL-1+ 
MNs and the growth of neurites which could reach more than 2 mm in length if big clusters were 
seeded in close proximity (>500 μM in diameter, ~1 cluster/cm2). ChAT expression was seen 
only after D40. In line with other reports, a semi-quantitative analysis of ISL-1 expression 
showed approximate MN yields of ~10-15% within the heterogeneous D35 populations derived 
from the differentiation of the clones (Supplementary Fig. S6). Further confirmation of MN 
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generation and identity was obtained by live fluorescent marking. For this, cells from 
differentiating D22 Nsphs from clone S3-63 were transduced with a lentiviral reporter vector 
expressing red fluorescent protein (RFP) under the MN-specific HB-9 enhancer/promoter 
33-35
. 
RFP expression could already be seen at D24, and the proportion of RFP+ cells increased 
strongly after D34, with MN yields similar to those estimated by ISL-1 immunochemistry 
(Supplementary Fig. S7). More accurate determination of MN yields was not possible due to the 
3D nature of the differentiating Nsphs. A similar proportion of RFP+ cells was still evident at 
D43, suggesting that most of the active MN production occurred on the 5
th
 week of MN 
differentiation (D34-D43) as it has been previously described in fixed hESC-derived MN cultures 
36
. 
 
The development of iPSCs into MNs is morphologically characterised by radial outgrowth of 
neurites from the centre of the differentiating Nsphs. In order to investigate patient-specific 
differences, the average neurite number (normalised by Nsph size) and length for each 
differentiating Nsph were analysed between D27 and D34. The method we used is illustrated in 
Supplementary Fig. S8, and the results shown in Fig. 3. Maternal clone M-26 and Type IV clone 
S1-28 showed trends with higher values than those observed in type III clones. The differences 
reached statistical significance in some cases, as indicated in Fig. 3. 
 
 
Co-culture of MNs and mouse myotubes 
 
iPSC-derived differentiating Nsphs were also co-cultured on differentiated mouse C2C12 
myoblasts. In all clones it was possible to observe specific co-localisation of TUJ1+ neurites with 
compact clusters of α-bungarotoxin-stained acetylcholine receptors (AChRs), indicative of 
neuromuscular junction (NMJ)-like structures (Fig. 4A). Aneural (in the absence of Nsphs) 
myoblast cultures showed expression of AChRs, but these mostly presented in a few small 
clusters dispersed along the fibres, without any particular localisation preference (Fig. 4B). 
Addition of differentiating Nsphs promoted clustering of AChRs in fibres surrounding the Nsphs 
(Fig. 4A). Quantitative analysis of the average size of the NMJ-like plaques showed significantly 
smaller structures in aneural cultures compared to the co-cultures, but no statistically significant 
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difference was found between the co-cultures of the family members (Fig. 4C). NMJ-like plaques 
in aneural cultures and in areas of co-cultures lacking direct contact with differentiating Nsphs 
were not significantly different in size, ruling out possible effects of factors secreted to the 
medium by the Nsphs. The presence of these smaller plaques in aneural cultures suggests that 
spontaneous AChR clustering occurs in myotubes but fails to mature in the absence of direct 
contact with MN terminals, while differentiating Nsphs from carrier mother and sisters were 
equally able to induce AChR clustering under these conditions. 
 
 
Variation of SMN and PLS3 levels during iPSC-MN differentiation 
 
To compare gene expression levels between SMA family members during the iPSC-MN 
differentiation process, five different cell culture stages were collected, including iPSCs (D0), 
EBs (D7), rosettes (D15), differentiating Nsphs (D35) and MNs (D42). We also included as a 
reference the parental fibroblasts from which the iPSC clones were generated. We followed the 
expression of SMN at the transcriptional and translational levels. iPSC clones showed some 
variations in mRNA expression levels of FL-SMN and Δ7-SMN, with a bell-shaped distribution in 
most cases, but fairly constant total SMN (tSMN) and FL-SMN to Δ7-SMN (FL/Δ7-SMN) mRNA 
ratios through the iPSC-MN differentiation stages (Supplementary Fig. S9). In contrast, all clones 
exhibited a gradual decrease in SMN protein during the MN differentiation process, irrespective 
of their initial absolute values at the iPSC stage (Supplementary Fig. S9). The exception to this 
pattern was due to a particularly low iPSC SMN protein value in clone M-26. To confirm whether 
the gradual decrease of SMN protein was idiosyncratic to the family or a general characteristic 
during iPSC-MN differentiation, we performed the same expression analyses in male wild-type 
and type I SMA iPSCs (4603 and SMA-19 respectively), obtaining similar results 
(Supplementary Fig. S9). We also analysed SMN protein levels grouping the samples as 
unaffected (wild-type control 4603 and carrier M-26) and SMA (all types). This confirmed 
statistically significant linear reductions of SMN protein levels during MN differentiation in both 
control and SMA groups (Fig. 5). 
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Since PLS3 has been reported as a modifier of the SMA phenotype in females, we also followed 
its expression at the transcriptional and translational levels during the iPSC-MN differentiation 
process. Remarkably, wild-type, carrier mother and SMA clones showed a gradual decrease in 
PLS3 mRNA and protein levels (Supplementary Fig. S10). When, as in the case of SMN, PLS3 
transcript and protein values were analysed in unaffected and SMA groups, we found statistically 
significant linear decays along the iPSC-MN differentiation process (Fig. 6). Similar results were 
obtained when considering only female individuals (see below). 
 
 
SMN and PLS3 measurements as biomarkers in SMA pathology 
 
Blood levels of FL-SMN mRNA and protein are often assessed in SMA studies, even though their 
predictive and diagnostic value is limited. We compared measurements of both parameters 
between the readily available fibroblasts from our subjects of study and their corresponding 
iPSC-MNs, finding no correlation (Fig. 7A, B). MN values of FL-SMN mRNA and protein were 
higher in the control clone 4603 than in the SMA carrier M-26 and all SMA clones; there was 
little difference in those MN values between carrier mother and SMA siblings in the discordant 
family. We assessed possible alterations in SMN transcription patterns due to epigenetic changes 
during fibroblast reprograming and iPSC-MN differentiation through DdeI restriction analysis of 
exons 6-8 of the SMN transcripts (SMN1 and SMN2). As previously reported for fibroblasts 
37
, we 
observed that at all developmental stages of the iPSC-MN differentiation essentially all FL-SMN 
transcripts from the sisters originated from their SMN2 genes, even though the SMN1 mutation is 
not expected to affect the transcription of the mutated gene (Supplementary Fig. S11). This points 
to possible nonsense–mediated decay of mutated SMN1 transcripts in this family. 
 
To perform statistical assessments of SMN-related parameters we compared the individuals of 
study by pooling together the values of their various cell types in the iPSC-MN differentiation 
process. Two parameters were highly consistent between cell types and showed strong albeit 
partial discriminatory power: FL/Δ7-SMN mRNA ratio and tSMN mRNA (Fig. 7C, D). The 
FL/Δ7-SMN mRNA ratio showed a statistically significant higher value in the 4603 control 
individual with two functional SMN1 alleles compared to the carrier mother with one functional 
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allele and the patients with no functional SMN1 allele (p<0.001, Fig. 7C). tSMN mRNA showed a 
statistically significant reduction in type I SMA samples compared to those from the 4603 control 
and all family members (p<0.001, Fig. 7D). For both parameters, samples from the carrier mother 
clustered with those from her type IIIa and type IV daughters rather than with the 4603 control, 
suggesting further effects of genotype. 
 
We also compared PLS3 mRNA and protein levels in fibroblasts from our subjects of study and 
their iPSC-derived MNs, again finding no correlation (Fig. 8A, B). Fibroblast values were higher 
than those in MNs for all individuals, both at mRNA and protein level. Given that PLS3 has been 
associated with a protective role in female SMA patients, we also performed a restricted 
comparison of PLS3 mRNA and protein values in fibroblast and MN samples from the unaffected 
M-26 carrier mother, the SMA type III S3-63 and S4-34 and the type IV S1-28 daughters, 
excluding the male samples. No correlation was found (Fig. 8A, B). Extending the PLS3 mRNA 
and protein level comparison to all cell types analysed and grouping the female samples as 
unaffected, type III or type IV SMA, we found no differences between groups, the exception 
being a statistically significant higher PLS3 protein level in the EBs of the unaffected carrier 
compared to the type III SMA siblings (Fig. 8C, D). In this all-female analysis we confirmed the 
significant linear trends for decreases in PLS3 mRNA and protein levels along the iPSC to MN 
differentiation (Fig. 8C, D), first noted when all subjects were included (Fig. 6A, B). 
Furthermore, it does not seem likely that the type IV/asymptomatic phenotype of S1-28 is 
associated with high PLS3 levels, given that both transcript and protein levels are within the 
range observed in the other SMA samples (Fig. 8A, B). 
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DISCUSSION 
 
The ability to differentiate iPSCs in vitro allows developmental studies as well as the 
establishment of disease models 
27-30
. In our study, fibroblasts from two SMA type IIIa sisters, 
their haploidentical SMA type IV/asymptomatic sibling and their unaffected mother (carrier of 
the same SMN1 mutation) were reprogrammed and differentiated into MNs. In this family, first 
described in 1995 
26
, SMN protein expression 
21
, SMN2 copy number, SMN2 transcript levels 
37
 
or PLS3 levels 
25
 do not explain the difference in phenotypes. 
 
The iPSC lines produced from the affected family in the present work have been thoroughly 
characterised and subsequently differentiated towards the MN lineage using an established 
protocol 
32
. The differentiating Nsphs thus produced showed the typical radial projection of TUJ-
1+ neurites upon attachment and were positive for MN markers ISL-1 and ChAT. Transduction 
with a lentiviral reporter driven by the MN-specific HB-9 promoter confirmed MN identity and 
the same temporal pattern as in differentiating hESCs 
36
. For phenotypic analyses we used 
differentiating MN cultures, in which compact Nsphs contained cells expressing relevant MN 
markers. By D28 of differentiation most of the cells from all iPSC clones in this study were 
positive for the MN precursor markers OLIG2 and p75-NGFR. Accurate quantification of MN 
yield was prevented by the EB-dependent MN differentiation method employed, but semi-
quantitative estimates based on the presence of ISL-1 protein or HB9-driven expression 
suggested these to be present in ~10-15% of the population. We attempted to obtain isolated MNs 
28,30
 but in our hands the viability of the single cells was severely affected and no downstream 
analyses were possible. It must be noted that a very recent 14-day protocol has described the 
differentiation of human MNs from human iPSCs cultured as single cells, with a yield of up to 
74% 
38
. However, the presence of a heterogeneous population in the MN cultures might be 
advantageous for the observation of SMA-related phenotypes. A recent study has shown, both in 
SMA mice in vivo and in human iPSC-derived SMA models, that SMA astrocytes show 
morphological and functional signs of activation preceding MN death 
39
. These results are 
congruent with the need for global restoration of SMN expression to normalize survival in SMA 
mouse models 
40-43
.  
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Three groups have previously reported the generation and MN differentiation of SMA type I 
iPSCs 
27-30
. Although with different timings, these groups have observed disease phenotypes 
including lower proportion/number of MNs after differentiation 
27-30
, decreased total MN cell 
body area 
27,28,30
, delayed neurite outgrowth 
29
, decreased number of neurites 
28
, shorter MN 
axons and growth cones 
30
 and presynaptic defects 
27
. We investigated MN cultures differentiated 
from representative chronic SMA iPSCs. The analysis of normalised neurite number and neurite 
length during the early period of MN differentiation (D27-D34) suggested that the SMA type 
IV/asymptomatic clone S1-28 resembled the maternal carrier clone M-26 more closely than the 
more affected type IIIa clones S3-63 and S4-32. These results suggest that the pathology and 
severity observed in the in vitro models of SMA may recapitulate developmental events in vivo in 
affected individuals 
44
. 
 
Research in SMA mouse models (reviewed in 
12
) and in human samples 
44
, suggests that the 
synaptic organization of NMJs is affected in SMA. Co-culture systems of myotubes and MNs are 
attractive as a way to dissect the structure and function of the NMJ 
45
, and in such cultures type I 
SMA iPSC–derived MNs have been reported to produce fewer and smaller endplates compared 
to heterozygote controls 
30
. We prepared similar cultures and observed a clearly different pattern 
in aneural cultures (differentiating myoblasts with no MN preparations added) compared to co-
cultures including differentiating MNs from the type IIIa/IV family. However, no differences 
were observed among the co-cultures of clones from the affected type IIIa/IV family, which may 
be due to a genuine lack of in vitro NMJ phenotype in these milder forms of the disease or to the 
relatively short time-frame in which the co-cultures were assessed. 
 
SMA is the result of a decrease in the amount of SMN protein, but the increased susceptibility of 
MNs is not understood. Developmental reductions in levels of SMN in human brain and animal 
spinal cord have been reported 
46-50
, although some examples of apparently steady levels in spinal 
cord and specifically in MNs have also been published 
50-52
. Several lines of study in SMA 
models have suggested that SMA is a developmental disorder, at least in the most severe cases 
53-
58
, and studies on human foetuses have provided significant evidence of prenatal onset of 
pathological defects in predicted type I SMA disease 
44,59-61
. We followed the levels of SMN 
protein during the in vitro differentiation of iPSCs to MNs and found a statistically significant 
12 
 
reduction, independent of sex, disease state or severity. This observation recapitulates the 
developmental reduction in spinal cord SMN detected in most models and suggests that MNs 
may complete differentiation with about 2-fold reduced levels of the protein. Whether the 
possible developmental reduction in SMN predisposes MNs to the selective defects and 
sensitivity observed in SMA remains to be demonstrated but it is an interesting working 
hypothesis. 
 
Transcriptional analyses of SMN genes show less consistency. Down-regulation of SMN 
promoter activity has been observed on in vitro differentiation of embryonic carcinoma cells 
towards the neuronal lineage 
62
, but increases in FL-SMN and Δ7-SMN transcripts have been 
described during differentiation of an hESC clone towards MNs following the same protocol 
employed here 
63
. Our own analyses using a variety of iPSC clones and differentiation batches 
show significant variability in FL-SMN and Δ7-SMN transcripts, in most cases showing a bell-
shaped distribution, while tSMN transcripts remain fairly constant (Supplementary Fig. S9). Of 
note, wild-type iPSC clone 4603 showed increased levels of FL-SMN transcript during 
differentiation, similar to the reported wild-type hESC clone 63, so it is possible that disease status 
has a bearing. However, as previously described 
37,64
, we found no correlation between FL-SMN 
transcript and protein levels in our iPSC differentiation studies, and protein levels were not 
reported in the hESC study 
63
.  
 
PLS3 has been reported to have a modifier role for SMA in discordant female siblings 
22-24,65,66
, 
perhaps due to its involvement in actin dynamics at the NMJ 
22,65
. We have previously found no 
correlation between SMA severity and PLS3 expression in whole blood, lymphoblasts or 
fibroblasts of the family studied here 
25
. We have now compared transcript and protein levels 
across the various stages of iPSC-MN differentiation, observing a statistically significant 
reduction in the levels of both mRNA (5-fold) and protein (2-fold) along the differentiation 
process, irrespective of sex, disease state or severity. These findings contrast with the previously 
reported increase in PLS3 expression found during the neural differentiation of PC12 cells 
22
 and 
further support the lack of a modifier role for PLS3 in the SMA family under study. 
 
One of the main aims for SMA therapeutic research is the definition of reliable biomarkers, 
13 
 
ideally measured in surrogate samples or cells of easy access 
64,67-72
. SMN2 copy number has 
consistently shown high correlation with SMA type 
13,14
, except in discordant SMA families such 
as the one studied here 
15-21,73
. Measurements of SMN transcripts and protein do not clearly 
distinguish between the diversity of SMA phenotypes 
10,64,67-71
, as we have confirmed here in 
iPSC-derived MNs. Using our dataset from iPSC-MN differentiation studies we concur that the 
FL/Δ7-SMN mRNA ratio is a robust parameter to distinguish control individuals with two 
functional SMN1 alleles and SMA patients, as described in cell cultures, foetal tissues and adult 
whole blood samples 
10,37,64
, but our results also indicate that it is not suitable to differentiate 
wild-type from the carrier mother. We have also confirmed that tSMN, a parameter that takes into 
consideration all isoforms of SMN transcript, distinguishes the type I SMA individual from all 
other subjects, as previously reported for peripheral blood leucocytes 
64,69
. This is consistent with 
the minimal number of functional SMN gene copies in severe SMA. Finally, our analyses of 
PLS3 transcript and protein levels show no usefulness for these parameters as SMA biomarkers. 
 
In summary, we have produced iPSCs from a discordant type IIIa/IV SMA family and 
differentiated them to MN populations, observing more modest neurite defects than previously 
reported for severe type I SMA. SMN protein analyses during the iPSC-MN differentiation 
process revealed a progressive decrease, which recapitulates previous developmental 
observations. PLS3 underwent similar reductions at transcriptional and translational levels. SMN 
and PLS3 reductions may be implicated in the increased vulnerability of MNs in SMA disease, 
but PLS3 levels in iPSC-derived MNs do not explain the phenotypic discrepancy between 
siblings of the discordant SMA family under study. Our measurements of SMN transcripts in 
iPSC-derived MN populations have confirmed their limited value as SMA biomarkers.  
14 
 
MATERIALS AND METHODS 
 
Patient samples 
 
We studied five individuals from a consanguineous Spanish SMA family (Fig. 1A and 
Supplementary Table S2). The unaffected mother (M), is a heterozygous carrier of the SMN1 
exon 3 mutation (c.399_402delAGAG). Patients S2, S3 and S4 suffer from proximal SMA type 
IIIa as defined by the criteria of the International SMA consortium 
5,74
. S1 was virtually 
asymptomatic until her thirties and at present walks normally, having minimum clinical and 
electromyographic manifestations. All sisters have four SMN2 copies 
15
. Fibroblasts were 
obtained from fresh skin biopsies for all individuals except for S2, now deceased, from whom a 
frozen fibroblast sample was used but failed to generate iPSC clones. Biopsies were taken with 
the understanding and written consent of each subject, using methods carried out in accordance 
with the approved guidelines and following experimental protocols approved by the Hospital de 
la Santa Creu i Sant Pau Clinical Research Ethics Committee. Clone 4603 (wild-type) and SMA-
19 (type I SMA, 
29
) are male iPSCs (Supplementary Table S2). 
 
 
Cell culture, vector production, fibroblast reprogramming and iPSC differentiation 
 
Cell line culture. Primary human fibroblast were maintained in Dulbecco’s modified Eagle’s 
medium high glucose with stable glutamine (DMEMg), supplemented with 10% foetal bovine 
serum (FBS), 1 mM sodium pyruvate, 1X non-essential amino acids (NEAAs), 1mM L-Ascorbic 
acid 2-phosphate (AA2P) and 10 ng/ml fibroblast growth factor 2 (FGF2). PLAT-E cells were 
maintained in DMEMg, supplemented with 10% FBS, 1 mM sodium pyruvate and 50 μM β-
mercaptoethanol. HEK293T cells and C2C12 mouse myoblasts (ATCC, CRL-1772) were 
maintained in DMEMg, supplemented with 10% FBS. To induce the formation of myotubes, 
FBS was replaced by 2% horse serum, and cells were cultivated in confluence. iPSC clones were 
maintained on mytomycin C growth-arrested immortalized human BJ1 fibroblasts (Clontech, Cat. 
No. C4001-1) in Stemedia NutriStem XF/FF Culture Medium (Stemgent, Cat. No. 130-095-543). 
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Vector production. Recombinant Moloney Murine Leukemia viral vectors (rMMLVs) were 
produced by the independent transfection of OCT4, SOX2, KFL4 AND c-MYC plasmids 
(Addgene plasmids 17220, 17225, 17226 and 17227) into PLAT-E packaging cells (Cell 
Biolabs). HIV-1 based lentiviral vectors (rH1LVs) were produced by co-transfection of 
pMDLg/pRRE, pRSV-REV, pMD2.VSV-G and pCCLsc_HB9_RFP_W in HEK293T cells as 
previously described 
75
. pCCLsc_HB9_RFP_W was kindly provided by Prof Fred Gage (Salk 
Institute, USA). 
 
iPSC reprogramming and culture. Fibroblasts were transduced with a 1:1:1:1 mix of the four 
rMMLVs after incubation with murine cationic amino acid transporter-1 (mCAT-1) gesicles as 
previously described 
76
. Valproic acid (VPA) supplementation was used for the first ten days. 
Potential iPSC colonies were selected on the basis of their embryonic stem cell (ESC) like-
morphology. Clones that survived and presented robust growth were expanded and frozen. 
 
Embryoid body (EB) formation. iPSCs were harvested by dispase treatment and grown in 
suspension for seven days. EBs were further plated in 0.1% gelatine-coated 24 well plates and 
cultured for seven more days before fixation.  
 
MN differentiation and transduction. MN differentiation was performed following a well–
established, EB-based protocol originally developed for hESCs 
32
. In brief, iPSCs were induced 
to neuroepithelial cells in the absence of morphogens in the first 2 weeks by generating EBs in 
the first week and plating them in neural differentiation medium (DMEM Nutrient mix F12 
supplemented with 1X N2, 1X NEAAs and 2 μg/ml heparin) in the second week. Between days 
10-17 neural tube like-rosettes became apparent within the plated clusters, and they were lifted by 
mechanical selection and grown in suspension as differentiating Nsphs for two weeks in the 
presence of 0.1 μM retinoic acid (RA) and 1 μM purmorphamine. The aggregates were split by 
incubation with accutase when their diameter size increased above 300 μm. Differentiating Nsphs 
containing MN progenitors were plated at day 28 on Poly-L Ornithine- Laminin (PO-Lam) 
coated surfaces and cultured in neural differentiation medium supplemented with 50 nM RA, 0.5 
μM purmorphamine, 0.1 μM cyclic adenosine monophosphate (cAMP), 200 ng/ml AA2P, 10 
ng/ml brain-derived neurotrophic factor (BDNF), 10 ng/ml glial cell-derived neurotrophic factor 
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(GDNF) and 10 ng/ml insulin-like growth factor1 (IGF-1) to generate post-mitotic MNs. This 
medium is referred to as complete MN differentiation medium and it was changed every other 
day. For transduction with rH1LVs, four D22 Nsphs were incubated in a microfuge tube for 2 
hours (37°C) in 200 μl of neural differentiation medium containing lentivector at a qPCR MOI of 
200 before plating. 
 
Co-culture system. iPSC-derived MN preparations were cultured on mice myotubes in order to 
observe the formation of NMJ-like structures. For this, C2C12 myoblasts were induced to 
differentiate in laminin-coated permanox TC chamber slides for four days. Four to six 
differentiating D39 Nsphs were then seeded on myotubes in a 1:1 mix of C2C12 differentiation 
medium and complete MN differentiation medium. Cells were then cultured for 3 days before 
fixation and staining with α–bungarotoxin (AChRs) and TUJ-1 antibody (neurites). The average 
size of AChR clusters was measured on captured images by manually demarcating the regions of 
interest based on the homogeneity and distribution of the AChR signal. Measurements were 
performed in at least five different fields from the iPSC-derived MNs/C2C12 myoblast co-
cultures of each clone; fields were selected in areas where neurites were present. Control 
measurements were also performed in fields where there was no direct contact between myotubes 
and the Nsphs or the neurites extending from them as well as in aneural cultures. 
 
 
Neurite length measurement 
 
Brightfield images of 5 small Nsphs (150-200 μm in diameter) per clone were taken on D27, 
D28, D29, D32 and D34 with an inverted Axio observer.A1 microscope (Zeiss) using a 2X 
objective. The number and length of all neurites and the surface area of the Nsphs were measured 
by a blinded observer using ImageJ software (NIH, MD, USA). The number of neurites per Nsph 
was normalised to the area of the corresponding Nsph. The values of normalised neurite numbers 
and neurite length were averaged for each Nsph separately. Neurites in large bundles were 
counted if they could be individually distinguished. Neurite length was measured from the edge 
of the cluster until the visually distinguishable end point. Neurite growth within the cluster was 
not assessed. 
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Immunocytochemistry 
 
Cells were fixed and stained with primary and secondary antibodies (Supplementary Table S3) 
following standard procedures. Images were taken with an inverted fluorescent Zeiss Axio 
observer.A1 microscope or an SP5 Leica confocal microscope. To estimate the yield of MNs in 
differentiated Nsphs preparations we counted total nuclei (using DAPI) and ISL-1 positive nuclei 
in areas where this was feasible, using imageJ (NIH) for both automatic processing and manual 
quantification.  
 
 
Alkaline Phosphatase (AP) staining 
 
Cells were fixed, stained with SIGMAFAST™ (Sigma-Aldrich. Cat No. B5655), washed and 
dried following manufacturer’s recommendations. Images were taken with a Leica DM IRB 
microscope. 
 
 
RNA isolation, cDNA synthesis, SMN transcripts origin and RNA expression analysis 
 
RNA isolation. RNA was extracted with TRIZOL (Invitrogen) following manufacturer’s 
instructions. 
 
cDNA synthesis. 1 μg of the corresponding RNA, and Moloney Murine Leukemia Virus Reverse 
Transcriptase (MMLV, Promega) were used. 
 
Origin of SMN transcripts. A segment corresponding to exons 6-8 was amplified by PCR, 
followed by DdeI restriction as previously described 
10
.  
 
RNA expression analysis and normalisation method. Reverse transcription polymerase chain 
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reaction (RT-PCR) and quantitative RT-PCR (qRT-PCR) analyses for the assessment of down 
regulation of transgenes in iPSCs were performed using previously described primers 
77
. RT-
PCRs were performed in a PCR gradient Thermal cycler TC-512 (Techne) using GoTaq Flexi 
DNA Polymerase (Promega) and qPCRs were performed in a Rotor-Gene 6000 real time rotary 
analyser (Corbett Life Science) using SensiMixPlus SYBR (Quantance). SMN and PLS3 
transcripts were quantified by qRT-PCR employing custom-made and commercial TaqMan 
probes 
37
. Samples were amplified and analysed in an ABI PRISM® 7900HT Sequence 
Detection System. A cDNA sample of SMA type II fibroblasts was systematically included along 
with the samples of study during the amplification of each target gene and its value arbitrarily set 
to one in order to be used as calibrator. The stability of at least six different housekeeping genes 
was analysed across all cell types included in the analyses using the geNorm VBA applet for 
Microsoft Excel 
78
. All qRT-PCR values were normalised to the geometric mean of the most 
stable reference genes determined across all pertinent samples 
78
: ribosomal protein L13a 
(RPL13A) and ribosomal RNA 18S (18S) for the assessment of transgene expression in iPSCs, 
and beta actin (ACTB), peptidylprolyl isomerase A (PPIA) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) for the quantification of SMN and PLS3. All primers were validated (i) 
by in silico specificity, (ii) by empirical specificity, through the amplification of a single product 
of the expected size, as observed in agarose gels; and (iii) in a qRT-PCR/qPCR run of serial 
dilutions of a control sample showing amplification efficiencies of 100% ± 10%, slopes of 3.3 ± 
10% and slopes CT target gene/CT reference gene of less than 0.1. A list of all primers used is 
shown in Supplementary Table S4. 
 
 
Western Blot 
 
Samples were harvested and Western blotting performed using standard procedures, with the 
antibodies listed on Supplementary Table S3. Detection and quantification of proteins was 
performed with an Odyssey Infrared Imaging System and application software V1 (LI-COR 
Biosciences). Target protein levels were normalised to the geometric mean of the values from 
alpha tubulin (TUBA), glucose phosphate isomerase (GPI1) and actin. A protein sample from 
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SMA type II fibroblasts was systematically included along the samples of study and its value 
arbitrarily set to one in order to be used as calibrator. 
 
 
Flow cytometry 
 
Cells co-expressing surface makers SSEA3 and TRA-1-81 were quantified by flow cytometry in 
a BD FACSCanto II with the BD FACSDiva Software (BD Biosciences).  
 
 
Karyotyping 
 
G-banding and mFISH were performed on metaphase chromosomes according to standard 
protocols.  
 
 
DNA fingerprinting 
 
Cell identity was verified by comparing the short tandem repeat (STR) profile at several loci. The 
profile was compared between iPSC clones, the original fibroblasts used for reprogramming and 
peripheral blood samples from the patients. The STRs studied were: D1S305 (chromosome 1), 
D2S443 and D2S291 (chromosome 2), D19S112 and D19S562 (chromosome 19) and INT25-2.0 
(chromosome X). 
 
 
Teratoma formation 
 
The teratoma assay was performed by Applied Stem Cell, Inc. (ASC, California, USA) following 
standard procedures. Methods were carried out in accordance with the approved guidelines, and 
all experimental protocols were approved by ASC’s Institutional Animal Care and Use 
Committee (IACUC). 
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Statistical analyses 
 
GraphPad Prism software was used for statistical analyses. Data were presented as mean ± 
standard error of the mean (SEM). Two-way ANOVA with Bonferroni’s post hoc test was used 
to analyse normalised neurite number, neurite length, SMN and PLS3 expression. For the 
analyses of linear trends of SMN and PLS3 expression one-way ANOVA with Dunnet’s and 
linear trend post hoc tests were employed. Kruskal-Wallis with Dunn’s post hoc test was used for 
the analysis of the area of AChR clusters. For correlation analyses Pearson correlation 
coefficients were calculated. Differences were considered statistically significant when the P 
value was <0.05 (*), <0.01 (**), <0.001 (***) or <0.0001 (****)  
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FIGURE LEGENDS 
 
Fig. 1. Pedigree chart, iPSC clones obtained and pluripotency assessment. (A) Diagram 
showing the carrier parents and siblings (black and white symbols) and the SMA type 
IV/asymptomatic and SMA type IIIa siblings (black circles) harbouring the SMN1 mutation 
(c.399_402delAGAG, exon 3). For each individual, the code and number of iPSC clones 
generated are presented. (B) In vitro differentiation potential of iPSC clones. EBs produced from 
selected iPSC clones from each individual generated cell derivatives of the three primary germ 
cell layers. Immunofluorescence analysis shows the expression of markers from ectoderm (TUJ1, 
red), mesoderm (smooth muscle actin, SMA, red; desmin, green) and endoderm (AFP, green). 
Nuclei were counterstained with DAPI. Scale bar=200 μm. Other abbreviations: TUJ1, neuronal 
class III beta tubulin; AFP, alpha fetoprotein; DAPI, 4’,6-diamidino-2-phenylindole. (C) In vivo 
differentiation potential of iPSC clones. Two million cells from selected iPSC clones were 
injected into Fox Chase SCID-beige mice and teratomas were obtained 36 days later. 
Hematoxylin and eosin staining shows the presence of pigmented cells (PigC) and neural rosettes 
(NR) of ectodermal origin; muscle, bone, cartilage and adipose tissue (AdT) of mesodermal 
origin; glands and duct of endodermal origin. Scale bar= 100 μm. 
 
Fig. 2. iPSC-MN differentiation process. Representative samples were collected during the 
differentiation process and the identities of specific cell types were confirmed by 
immunocytochemistry: OCT4+ iPSCs at D0, EBs at D7, PAX6+/SOX1+ rosettes at D15, 
OLIG2+ differentiating Nsphs containing MN progenitors at D28, ISL-1+ MNs at D35 and 
ChAT+ MNs at D42. Scale bar: 100 μm. Abbreviations: EBs, embryoid bodies; Nsphs, 
differentiating neuroepithelial-derived spheres; W, week; OCT4, POU class 5 homeobox 1; 
PAX6, Paired box gene 6; SOX1, Sex determining region Y-box 1; OLIG2, Oligodendrocyte 2; 
ChAT, choline acetyl transferase.  
 
Fig. 3. Neurite growth analysis in differentiating iPSC-derived Nsphs containing MN 
progenitors. Small D26 Nsphs (150-200 μm in diameter) from the indicated iPSC clones were 
plated in Poly-L-Ornithine-laminin coated dishes for consecutive neurite length measurements 
over 8 days, as described in Materials and Methods. (A) Average number of neurites per Nsph 
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normalised to Nsph size. (B) Average neurite length. Data are presented as mean ± SEM. * , 
p<0.05; ** , p<0.01;*** , p<0.001. 
 
Fig. 4. Co-cultures of differentiating Nsphs and C2C12 myoblasts. (A) Co-culture of iPSC 
derived MNs from the family under study and mouse myotubes. D39 Nsphs from differentiating 
iPSC clones were seeded onto differentiating C2C12 mouse myoblasts and cultured for 3 days in 
a mixed MN/muscle medium. Acetylcholine receptors (AChRs), identified by α-bungarotoxin 
staining (red), clustered preferentially in fibres located around TUJ1+ (green) neurites emerging 
from the differentiating Nsphs. Confocal imaging suggests that at least some neurite terminals co-
localised with AChR plaques. The same pattern was observed in co-cultures of all family clones. 
Arrows on Merged panel point to clusters of AChRs co-localising with neurite terminals, shown 
at higher magnification on the last column of images. Nuclei were counterstained with DAPI 
(blue). Scale bar: 20 μm. Abbreviations: TUJ1, neuronal class III beta tubulin; DAPI, 4’,6-
diamidino-2-phenylindole. (B) Comparison of AChR clustering in aneural myoblast cultures and 
neural co-cultures. C2C12 mouse myoblasts cultured aneurally show diffuse location of AChRs, 
with few, small clusters, whereas their co-culture with D39 Nsphs (for 3 days) induces localised 
expression and higher clustering. The lower images show how AChR clustes were measured by 
manually demarcating the regions of interest. Scale bar: 50 μm. (C) Average size of AChR 
clusters formed upon iPSC-MN/C2C12 myotube interaction. The quantitation was performed 
with family clones, using aneural cultures as controls. Data are presented as mean ± SEM. * , 
p<0.05.  
 
Fig. 5. Decay in SMN protein levels during iPSC-MN differentiation. (A) SMN protein levels 
were analysed by western blot at the indicated differentiation stages and samples grouped as 
unaffected or SMA. Statistical significance for differences between differentiation stages or for 
trends in protein reduction is indicated. No significant differences were found between unaffected 
and SMA groups at any cell stage. Data are presented as mean ± SEM. * , p<0.05; ** , p<0.01; 
*** , p<0.001; **** , p<0.0001. (B) Representative western blot showing decay in SMN protein 
during the iPSC-MN differentiation of clone S3-63. Abbreviations: EBs, embryoid bodies; 
Nsphs, differentiating neuroepithelial-derived spheres; MNs, motor neurons; TUBA, alpha 
tubulin; GPI1, glucose phosphate isomerase. 
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Fig. 6. Decay in PLS3 levels during iPSC-MN differentiation. Levels of PLS3 mRNA (A) and 
protein (B) are grouped for unaffected individuals (wild-type control and carrier M-26) and SMA 
patients (type I SMA, type IIIa/IV SMA family members) in the various cell types harvested 
during the iPSC-MN differentiation process. Arrows represent the statistical significance of the 
linear trend for gradual decrease along the MN differentiation process for each group. No 
significant differences were found between control and SMA groups at any cell stage. Data are 
presented as mean ± SEM. ** , p<0.01;*** , p<0.001; **** , p<0.0001. (C) Representative 
western blot showing decay in PLS3 protein during the iPSC-MN differentiation of clone S3-63. 
Abbreviations: EBs, embryoid bodies; Nsphs, differentiating neuroepithelial-derived spheres; 
MNs, motor neurons; TUBA, alpha tubulin; GPI1, glucose phosphate isomerase. 
 
Fig. 7. Comparative assessment of SMN measurements. (A) The expression of FL-SMN 
mRNA and (B) the level of protein in paired fibroblast and their corresponding differentiated MN 
cultures were compared in all individuals under study; n=2. Parental fibroblasts from iPSC clone 
SMA-19 were not available and in this case fibroblasts from another type I SMA patient (with 
two SMN2 copies and no SMN1) were used as an alternative reference. Pearson correlation 
coefficients (R) for values in fibroblasts and MNs are shown for all individuals combined and for 
the type IIIa/IV family. Average values for (C) FL/Δ7-SMN mRNA ratio and (D) tSMN mRNA 
from iPSCs, EBs, rosettes, Nsphs and MNs were pooled for each individual for comparison 
among SMA genotypes and phenotypes. Data are presented as mean ± SEM. * , p<0.05; ** , 
p<0.01;*** , p<0.001. Abbreviations: EBs, embryoid bodies; Nsphs, differentiating 
neuroepithelial-derived spheres; MNs, motor neurons. 
 
Fig. 8. Comparative assessment of PLS3 measurements. (A) The expression of PLS3 mRNA 
and (B) the level of protein in paired fibroblast and their corresponding differentiated MN 
cultures were compared in all individuals under study; n=2. Parental fibroblasts from iPSC clone 
SMA-19 were not available and in this case fibroblasts from another type I SMA patient (with 
two SMN2 copies and no SMN1) were used as an alternative reference. Pearson correlation 
coefficients (R) for values in fibroblasts and MNs are shown for all individuals combined and for 
the type IIIa/IV family. PLS3 mRNA (C) and protein (D) values were compared between the 
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female individuals of this study (carrier unaffected mother, type IIIa SMA siblings and type IV 
SMA sibling) across all cell types available. Data are presented as mean ± SEM. ** , p<0.01;*** 
, p<0.001; **** , p<0.0001. Abbreviations: EBs, embryoid bodies; Nsphs, differentiating 
neuroepithelial-derived spheres; MNs, motor neurons. 
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SUPPLEMENTARY INFORMATION 
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Supplementary Table S1. STR profile of selected iPSC clones, their parental fibroblasts and peripheral blood from the 
donors. Values shown correspond to number of repeats. 
 
 
Chrom 1 
D1S305 
Chrom 2 
D2S443 
Chrom 2 
D2S291 
Chrom 19 
D19S112 
Chrom 19 
D19S562 
Chrom X 
INT25-2.0 
M-26 iPSCs 25, 27 11, 13 18, 18 11,12 13, 33 15, 17 
M Fibroblasts 25, 27 11, 13 18, 18 11,12 13, 33 15, 17 
M Peripheral blood 25, 27 11, 13 18,18 11,12 13, 33 15, 17 
S1-28 iPSCs 27, 27 13, 13  18, 26 11,12 13, 33 15, 16 
S1 Fibroblasts 27, 27 13, 13 18, 26 11,12 13, 33 15, 16 
S1 Peripheral blood 27, 27 13, 13 18, 26 11,12 13, 33 15, 16 
S3-63 iPSCs 27, 31 13, 13 18, 26 11, 16 13, 27 16, 17 
S3 Fibroblasts 27, 31 13, 13 18, 26 11, 16 13, 27 16, 17 
S3 Peripheral blood  27, 31 13, 13 18, 26 11, 16 13, 27 16, 17 
S4-32 iPSCs 25, 31 11, 12 18, 18 12, 12 33, 33 15, 16 
S4 Fibroblasts 25, 31 11, 12 18, 18 12, 12 33, 33 15, 16 
S4 Peripheral blood 25, 31 11, 12 18, 18 12, 12 33, 33 15, 16 
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Supplementary Table S2. Clinical, molecular and cellular data of the individuals included in this study and the iPSCs derived 
from them. NA: not applicable. ND: not determined. Data concerning the members of the Spanish family of study (M, S1, S3 and S4) 
have been previously described (Bernal et al., 2011; Also-Rallo et al., 2011). 
Individual 4603 SMA-19 M S1 S3 S4 
Race Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian 
Sex Male Male Female Female Female Female 
Genotype NA 
Homozygous for 
deletion of exons 7 
and 8 of the SMN1 
gene 
Carrier of 
c.399_402delAGAG 
mutation in SMN1 
gene 
Homozygous for 
c.399_402delAGAG 
mutation in SMN1 
gene 
Homozygous for 
c.399_402delAGAG 
mutation in SMN1 
gene 
Homozygous for 
c.399_402delAGAG 
mutation in SMN1 
gene 
SMN2 copy 
number ND 2 3 4 4 4 
Origin of FL-SMN 
transcripts SMN1 and SMN2 All from SMN2 SMN1 and SMN2 Mostly from SMN2 Mostly from SMN2 Mostly from SMN2 
Age of onset of 
weakness NA <6 months NA NA 18 months 18 months 
Wheelchair bound 
(age they stopped 
being able to walk) NA Never walked NA NA 14 years 8 years 
Electromyography 
results NA Denervation NA Minimal changes Denervation Denervation 
Diagnosis Unaffected SMA type I Unaffected 
Asymptomatic or 
SMA type IV SMA type IIIa SMA type IIIa 
Cell type used for 
iPSC 
reprogramming 
Fibroblasts harvested 
from skin biopsy. 
Coriell Cat No 
GM04603 
Fibroblasts harvested 
from eye lens. Coriell 
Cat No GM09677 
Fibroblasts harvested 
from skin biopsy 
Fibroblasts harvested 
from skin biopsy 
Fibroblasts harvested 
from skin biopsy 
Fibroblasts harvested 
from skin biopsy 
Age at sample 
collection Adult. Not Specified 2 years >60 45 38 36 
iPSC clone 
selected  
4603. Unpublished, 
iSTEM (France) 
SMA-19. Chang et 
al., 2011 M-26  S1-28 S3-63 S4-32 
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Supplementary Table S3. Antibodies used in the present study. 
Antibody name Manufacturer 
Catalogue 
number Concentration/Dilution Technique 
Alexa Fluor® 647 anti-human 
SSEA-3 BioLegend 330308 0.125 μg/ 5x105 cells Flow cytometry 
Alexa Fluor® 647 Rat IgM, κ 
Isotype Ctrl BioLegend 400813 0.125 μg/ 5x105 cells Flow cytometry 
PE anti-human TRA-1-81 BioLegend 330708 0.125 μg/ 5x105 cells Flow cytometry 
PE Mouse IgM, κ Isotype Ctrl BioLegend 401609 0.125 μg/ 5x105 cells Flow cytometry 
Mouse anti-OCT4 Chemicon MAB4401 1 in 500 
 
Immunocytochemistry 
Mouse anti-TRA-1-60  Chemicon MAB4360 1 in 500 
 
Immunocytochemistry 
Rabbit anti-SOX2  Chemicon AB5603 1 in 500 
 
Immunocytochemistry 
Mouse anti NANOG Abcam AB62734 1 in 100 
 
Immunocytochemistry 
Mouse anti-Smooth muscle actin 
(SMA) DAKO M0851 1 in 100 
 
Immunocytochemistry 
Rabbit anti-Desmin Abcam AB15200 1 in 200 
 
Immunocytochemistry 
Rabbit anti-Alpha Fetoprotein 
Molecular 
Probes 18-0055 1 in 100 
 
Immunocytochemistry 
Goat anti-SOX17 
R&D 
systems AF1924 1 in 100 
 
Immunocytochemistry 
Goat  anti-SOX1 
R&D  
systems AF3369 1 in 500  
 
Immunocytochemistry 
Mouse anti-PAX6 DSHB Supernatant 1 in 500 
 
Immunocytochemistry 
Goat anti- ISLET1  
R&D 
systems AF1837 1 in 50 
 
Immunocytochemistry 
Goat anti-Choline 
acetyltransferase (ChAT) Chemicon AB144P 1 in 50 
 
Immunocytochemistry 
 5 
Rabbit  Anti-Neuronal class III 
beta tubulin (TUJ1) Sigma T 2200 1 in 3000 
 
Immunocytochemistry 
α-Bungarotoxin, Alexa Fluor® 
555 Conjugate 
Molecular 
Probes B35451 1 in 500 
 
Immunocytochemistry 
Alexa Fluor 568 donkey anti - 
mouse IgG 
Molecular 
probes A10037 1 in 1000 
 
Immunocytochemistry 
Alexa Fluor® 488 donkey anti-
mouse IgG (H+L) 
Molecular 
probes A21202 1 in 1000 
 
Immunocytochemistry 
Alexa Fluor® 488 donkey anti-
goat IgG (H+L) 
Molecular 
probes A-11055 1 in 1000 
 
Immunocytochemistry 
Alexa Fluor® 546 donkey anti-
goat IgG (H+L) 
Molecular 
probes A11056 1 in 1000 
 
Immunocytochemistry 
Alexa Fluor® 555 goat anti-
rabbit IgG (H+L) 
Molecular 
probes A21428 1 in 1000 
 
Immunocytochemistry 
Alexa Fluor® 488 goat anti-
rabbit IgG (H+L) 
Molecular 
probes A-11034 1 in 1000 
 
Immunocytochemistry 
Mouse anti-survival motor 
neuron (SMN) 
BD 
Biosciences 610646 1 in 5000 Western blot 
Rabbit Anti-T Plastin antibody ABCAM AB128690 1 in 1000  Western blot 
Rabbit anti-Alpha tubulin ABCAM AB4074 1 in 2000 Western blot 
Mouse anti-Actin  DSHB 
JLA20. 
Supernatant 1 in 100 Western blot 
Mouse anti- Glucose phosphate 
isomerase (GPI1) DSHB 
CPTC-GPI-
1. 
Supernatant 1 in 100 Western blot 
IRDye 800CW goat anti-mouse  LI-COR 92632210 1 in 2000 Western blot 
Goat anti-Rabbit alexa flour 680  
Molecular 
Probes A21076 1 in 5000 Western blot 
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Supplementary Table S4. Primer sequences for RT-PCR/qPCR reactions. 
 
Gene Forward primer sequence 
(5’  3’) 
Reverse primer sequence 
(5’  3’) 
Taqman Probe (5’  3’) Reference 
c-MYC endogenous TGCCTCAAATTGGACTT
TGG 
GATTGAAATTCTGTGTA
ACTGC 
 Park et al., 2008 
c-MYC total ACTCTGAGGAGGAACA
AGAA 
TGGAGACGTGGCACCT
CTT 
 Park et al., 2008 
c-MYC transgene TGCCTCAAATTGGACTT
TGG 
CGCTCGAGGTTAACGA
ATT 
 Park et al., 2008 
OCT4 endogenous CCTCACTTCACTGCACT
GTA 
CAGGTTTTCTTTCCCTA
GCT 
 Park et al., 2008 
OCT4 total AGCGAACCAGTATCGA
GAAC 
TTACAGAACCACACTC
GGAC 
 Park et al., 2008 
OCT4 transgene CCTCACTTCACTGCACT
GTA 
CCTTGAGGTACCAGAG
ATCT 
 Park et al., 2008 
KFL4 endogenous GATGAACTGACCAGGC
ACTA 
GTGGGTCATATCCACTG
TCT 
 Park et al., 2008 
KFL4 total TCTCAAGGCACACCTG
CGAA 
TAGTGCCTGGTCAGTTC
ATC 
 Park et al., 2008 
KFL4 transgene GATGAACTGACCAGGC
ACTA 
CCTTGAGGTACCAGAG
ATCT 
 Park et al., 2008 
SOX2 endogenous CCCAGCAGACTTCACA
TGT 
CCTCCCATTTCCCTCGT
TTT 
 Park et al., 2008 
SOX2 total AGCTACAGCATGATGC
AGGA 
GGTCATGGAGTTGTACT
GCA 
 Park et al., 2008 
SOX2 transgene CCCAGCAGACTTCACA
TGT 
CCTTGAGGTACCAGAG
ATCT 
 Park et al., 2008 
RPL13A CTACGACAAGAAAAAG
CGGA 
GCCCCAGATAGGCAAA
C 
 Designed here 
18S GAGGATGAGGTGGAAC
GTGT 
TCTTCAGTCGCTCCAGG
TCT 
 Designed here 
 7 
SMN 6-8 CTCCCATATGTCCAGAT
TCTCTTG 
CTACAACACCCTTCTCA
CAG 
 Soler-Botija et al., 2005 
Full-length Survival 
motor 
neuron (FL-SMN) 
GCT GAT GCT TTGGGA 
AGTATGTTA 
CACCTTCCTTCTTTTTG
ATTTTGTC 
FAM-
TTTCATGGTACATGAGT
GGCTATCATACTGGCTA
TTAT-MGBNFQ 
Also-Rallo et al., 2011 
SMN Delta 7 isoform 
(Δ7-SMN) 
TGGACCACCAATAATT
CCCC 
ATGCCAGCATTTCCATA
TAATAGCC 
FAM-
ACCACCTCCCATATGTC
CAGATTCTCTTGATG-
MGBNFQ 
Also-Rallo et al., 2011 
Total SMN (FL-SMN 
+ Δ7-SMN) 
NA Applied Biosystems Cat 
No. Hs00165806_m1  
Plastin 3  NA Applied Biosystems Cat 
No. Hs00192406_m  
Beta actin NA Applied Biosystems Cat 
Hs99999903_m1 
Peptidylprolyl 
isomerase A 
NA Applied Biosystems 
Hs99999904_m1 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
NA Applied Biosystems Cat 
No Hs02758991_g1 
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Supplementary Figure 1 
 
 
Supplementary Fig. 1. Expression of pluripotency markers in selected iPSC clones. Alkaline 
phosphatase (AP) staining and immunofluorescence analysis show the expression of the 
pluripotency markers AP, OCT4, NANOG, SOX2, and TRA-1-60 in representative colonies of 
iPSC clones. Scale bar= 200 μm. 
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Supplementary Figure 2 
 
 
Supplementary Fig. 2. Quantitative assessment of pluripotency. Multi-parameter flow 
cytometry was performed on selected iPCS clones in order to determine the proportion of cells 
co-expressing the pluripotency markers SSEA3 and TRA 1-81. (A) Control samples after 
calibration and set up of appropriate thresholds. (B) The high percentage of double positive 
SSEA3/TRA1-81 cells in clones M-26, S3-63 and S4-32, indicated on the top right corner of the 
corresponding dot-plot, suggests low tendency for spontaneous differentiation in culture. Clone 
S1-28 shows a moderate propensity to differentiate. Abbreviations: FMO: fluorescence minus 
one.  
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Supplementary Figure 3 
 
 
 
Supplementary Fig. 3. Down-regulation of transgenes in selected iPSCs. The down-
regulation of the four transgenes, OCT4, SOX2, c-MYC and KFL4, was assessed by quantitative 
and standard reverse transcription (RT)-PCR. (A) The endogenous and total (endogenous + 
exogenous) expressions of the pluripotency genes was quantified by qRT-PCR. Gene expression 
was normalized to the geometric mean of RPL13 and 18S and plotted (log10 scale) relative to the 
expression of EP2102 carcinoma cells, which was arbitrarily set to 1. Data are presented as mean 
± standard deviation. (B) The expression of the transgenes was measured through RT-PCR with 
primers targeting retroviral-specific sequences. 18S is shown as a positive amplification and 
loading control. BJ1 human fibroblasts (BJ1), IMR90 human fibroblasts undergoing 
reprogramming and harvested 4 days post transduction (IMR90 D4) and H9 human embryonic 
stem cells (hESCs) were included in the analysis as references.   
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Supplementary Figure 4 
 
 
 
Supplementary Fig. 4. Karyotype analysis of selected iPSC clones. mFISH (clones M-26 and 
S1-28) and G-banding (clones S3-63 and S4-32) were performed on metaphase spreads. Clone 
name, passage number at the time of cell cycle arrest and cell fixation and karyotype are shown. 
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Supplementary Figure 5 
 
 
 
Supplementary Fig. 5. Rosette formation and neuroepithelial identity. Selected iPSC clones 
were grown as embryoid bodies (EBs) for seven days and then plated in gelatine-coated plates 
until rosette formation. (A) Several neural–tube like rosettes can be seen within each EB cluster 
14-15 days after the start of the differentiation protocol. (B) Co-expression of PAX6 (red) and 
SOX1 (green) confirmed neuroepithelial identity. Images A and B for each clone are taken from 
different fields/wells. Scale bars = 100 μm. 
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Supplementary Figure 6 
 
 
 
Supplementary Fig. 6. Generation of post-mitotic MNs. Rosettes from selected iPSC clones 
were grown in suspension as Nsphs for 13 days and plated on poly-L ornithine-laminin coated 
coverslips for differentiation. Bright field microscopy shows long neurites extending from the 
clusters of all clones a few days after plating. Immunofluorescence analysis confirmed MN 
identity by ISL-1 (red) and ChAT (green) expression on days 35 and 46 of MN differentiation, 
respectively. Nuclei were counterstained with DAPI. The images shown for each clone were 
taken from different fields/wells. Scale bar = 50 μm. Abbreviations: ISL-1, Insulin gene enhancer 
protein Islet-1; ChAT, Choline acetyl transferase; DAPI, 4’,6-diamidino-2-phenylindole.  
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Supplementary Figure 7 
 
 
 
Supplementary Fig. 7. Live follow-up of MN production in differentiating iPSC cultures. 
D22 Nsphs from iPSC clone S3-63 were transduced with a lentiviral vector expressing RFP 
under the control of the HB9 MN-specific enhancer/promoter. The proportion of RFP-positive 
cells increased over time through days 24, 27, 34 and 43 of MN differentiation (corresponding to 
days 2, 5, 12 and 21 post-transduction, respectively). Images on the bottom row show the typical 
spread of RFP expression seen inside the Nsphs. Scale bar = 100 μm. Abbreviations: RFP, red 
fluorescent protein. 
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Supplementary Figure 8 
 
 
 
Supplementary Fig. 8. Method employed to perform neurite measurements using ImageJ 
software. To obtain clearly distinguishable neurites, small differentiating Nsphs were plated 
sparsely (top). Captured images were analysed to identify individual neurites (middle) and obtain 
length measurements (bottom).  
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Supplementary Figure 9 
 
 
 
Supplementary Fig. 9. Patient-specific variation of SMN mRNA and protein levels during 
iPSC-MN differentiation. The average expression of FL-SMN mRNA, SMN protein, Δ7-SMN 
mRNA, tSMN mRNA and FL/Δ7-SMN mRNA ratio is shown for all cell types harvested during 
the iPSC-MN differentiation process of each iPSC clone. Samples were calibrated to a common 
stock derived from type II SMA fibroblasts. Abbreviations: tSMN: total SMN transcript; EBs: 
embryoid bodies; Nsphs: Neuroepithelial-derived spheres; N: number of samples.  
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Supplementary Figure 10 
 
 
Supplementary Fig. 10. Patient-specific variation of PLS3 mRNA and protein levels during 
iPSC-MN differentiation. The average expression of PLS3 mRNA and protein is shown for all 
cell types harvested during the iPSC-MN differentiation process of each iPSC clone. Samples 
were calibrated to a common stock derived from type II SMA fibroblasts. Abbreviations: tSMN: 
total SMN transcript; EBs: embryoid bodies; Nsphs: Neuroepithelial-derived spheres; N: number 
of samples. 
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Supplementary Figure 11 
 
 
Supplementary Fig. 11. Allelic origin of SMN transcripts. (A) Diagram showing the 
amplification and restriction pattern analysis performed for the determination of the locus from 
which FL-SMN transcripts originate. Top row shows relevant SMN transcript regions subjected to 
amplification, including exons, primers and the diagnostic DdeI restriction site present in SMN2 
PCR products. The middle row displays the expected RT-PCR products (504-bp and 450-bp 
fragments, corresponding to FL-SMN and Δ7-SMN transcripts respectively). The bottom row 
indicates expected fragments following DdeI digestion of the PCR products (SMN1 products are 
not digested, but FL-SMN2 transcripts generate 382-bp and 122-bp fragments, while Δ7-SMN2 
transcripts produce 328-bp and 122-bp fragments, respectively). (B) DdeI restriction analysis of 
iPSC (D0), EBs (D7), rosettes (D15), Nsphs (D28) and MN (D42) amplification products from 
the six clones under study. Abbreviations: EBs, embryoid bodies; Nsphs: Neuroepithelial-derived 
spheres. 
